You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeted Treatment of Recurrent Small Cell Lung Cancer with Anti-AbnV2 Antibodies

    SBC: Woomera Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): There is currently no effective treatment for recurrent small-cell lung cancer (rSCLC). The objective of this project is to utilize a monoclonal antibody, Abner, to develop new, rational, and successful treatment of rSCLC. The hypothesis being tested is that an abnormal vasopressin type 2 receptor (AbnV2R) present on these tumors will provide a sensitive, tumor ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Dynamic Perturbation Training System for ACL Rehabilitation

    SBC: Simbex LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): Anterior cruciate ligament (ACL) injuries are a significant problem for athletes, and women in particular. Both surgical and non-surgical treatment options exist, with the ultimate goal of regaining joint stability, knee kinematics, and quadriceps strength compared to the uninjured contralateral limb to allow full return of function and activity level and to p ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Depletion of Dendritic Cells by Immunotoxin as Therapy for Myocardial Infarction

    SBC: CELDARA MEDICAL, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): MI is the leading cause of death in the developed world, including the United States. In 2005 over 8.1 million Americans had an MI; 30% died before reaching hospital and 10% died after hospitalization. It is the 70% whoreach hospital that we believe we can help - a million lives in the balance and an improved quality of life for millions more - in the US alone. ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. ChNKG2D-Targeted Cellular Cancer Therapy: Phase I Clinical Trial

    SBC: CELDARA MEDICAL, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): The global burden of cancer doubled between 1975 and 2000. Cancer became the leading cause of death worldwide in 2010, and is projected to double again by 2020 and to triple by 2030. This horrible disease has touched each of us, and despite enormous investments in prevention and treatment, its impact continues to accelerate. Ideally, any cancer therapy should ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease

    SBC: Immunext, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): The immune system depends upon an exquisite balance between positive and negative signals to maintain proper function. However, disruptions of this balance can lead to inappropriate responses: for example loss of negative regulation can result in autoimmunity. VISTA (V-region Immunoglobulin-containing Suppressor of T cell Activation), is a recently identified n ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. An Unobtrusive, Multi-individual Gait Monitor

    SBC: RESPONSE APPLICATIONS, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): We will develop an instrument to improve the healthcare of the most frail members of the elderly community. This population; elderly or recovering patients living at home or in an extended care facility is too frail toleave this environment and, as such, is subject to significantly reduced physical activity. Although numerous studies have confirmed that contin ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Safe and effective anti CD154 antibodies for therapeutic intervention

    SBC: IMMURX LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): In both animal proof of concept studies and preliminary clinical trials, there is ample data demonstrating the potential therapeutic benefits o CD154 blockade for treatment of autoimmune diseases and organ transplantation. However, development of ?CD154 as a therapeutic has been impeded by antibody toxicity observed in early clinical trials. With nearly 50 mill ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Tetravalent Vaccines for Dengue Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Dengue virus infection is an emerging disease and an expanding global health problem. More than one-third of the world's population is at risk for transmission in tropical and subtropical areas and vaccines are an urgent public health priority. Although dengue rarely occurs in the continental United States, it is endemic in Puerto Rico, and in many popular ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Vaccines are urgently needed to slow the spread of the HIV/AIDS epidemic, and immunogens that can induce neutralizing antibodies remain an important goal of vaccine research. An increasing number of human monoclonal antibodies (mAbs) have been isolated in recent years from individuals who show remarkably broad and potent neutralizing responses. Coupled with pas ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Therapeutic Vaccines for Chronic HBV

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is a noncytopathic, hepatotropic DNA virus that results in a self-limited acute infection in a majority of otherwise healthy individuals but can also cause chronic infection, particularly in newborns infected by vertical transmission. Chronic hepatitis B infection is a significant global health issue directly affecting 350 million people ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government